Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 21, 2025 08:00 ET | Source: VeonGen GmbH

VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease

MUNICH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- VeonGen Therapeutics, a clinical-stage genetic medicine company developing next-generation gene therapies, today announced that the U.S. Food and Drug...
August 12, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

FDA grants Fast Track Designation to AAVantgarde's AAVB-039 gene therapy for Stargardt disease, advancing development for this rare cause of vision loss.
July 23, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 43rd Annual Meeting July 29-August 2

Alkeus Pharmaceuticals announces gildeuretinol data presentations during the American Society of Retina Specialists (ASRS) 43rd Annual Meeting.
July 15, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

FDA clearance enables AAVantgarde's AAVB-039 to enter Phase 1/2 CELESTE trial in Stargardt disease, restoring robust ABCA4 expression.
April 28, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

AAVantgarde Bio appoints Rasmus Holm-Jorgensen as CFO to support growth and advance AAV gene therapies for inherited retinal diseases.
April 24, 2025 10:59 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals announces presentations of gildeuretinol data in Stargardt and GA during ARVO May 4-8
March 31, 2025 02:00 ET | Source: AAVantgarde Bio

AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances

AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances
March 10, 2025 03:00 ET | Source: AAVantgarde Bio

AAVantgarde announces 2 presentations at ARVO 2025 annual meeting: LUCE-1 clinical trial data from Usher 1B program & NHP GLP data from Stargardt disease program

AAVantgarde announces 2 presentations at ARVO 2025 annual meeting
February 25, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...
February 11, 2025 08:30 ET | Source: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025

CAMBRIDGE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today...